Vogelgrippe-Aktie...Wahnsinnseinstiegschance!!! - 500 Beiträge pro Seite
eröffnet am 23.03.06 13:44:42 von
neuester Beitrag 24.03.06 16:30:10 von
neuester Beitrag 24.03.06 16:30:10 von
Beiträge: 15
ID: 1.049.400
ID: 1.049.400
Aufrufe heute: 0
Gesamt: 1.506
Gesamt: 1.506
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 421 | |
| vor 41 Minuten | 135 | |
| gestern 19:02 | 114 | |
| gestern 21:36 | 79 | |
| gestern 23:08 | 74 | |
| vor 20 Minuten | 73 | |
| gestern 23:36 | 68 | |
| vor 18 Minuten | 60 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.503,00 | +0,34 | 294 | |||
| 2. | 2. | 174,10 | -2,09 | 108 | |||
| 3. | 3. | 10,230 | +447,06 | 108 | |||
| 4. | 4. | 0,1935 | +2,38 | 77 | |||
| 5. | 7. | 0,9600 | -14,29 | 70 | |||
| 6. | 5. | 4,1725 | -5,17 | 64 | |||
| 7. | 6. | 1,1100 | -3,48 | 60 | |||
| 8. | 8. | 5,9840 | -1,55 | 48 |
Feedback
Die Aktie hat eine beispiellose Aufwärtsentwicklung bis gestern Abend hingelegt. Sie ist in der Spitze gestern bis 5,02$ nach oben geschossen, um dann auf 3,22$ zu schließen. Diese Aktie zeichnet sich durch ein riesiges Wachstumspotential aus und bietet allen eine super neue Einstiegschance. Kann sein, daß wir nächste Woche schon wieder neue Höchststände sehen werden. Keine Zockerei, sondern ein phantastischer Wert, der seinen Weg nach oben wieder machen wird. Weiter strong buy.
Company Expands Drug Delivery Platform Patent Portfolio
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has been granted a patent by the Mexico National Registry of Patents titled "Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles." The patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.
The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.
"We are pleased to augment our Latin American patent protection as we continue with our Generex Oral-lyn(TM) commercialization efforts in the region," said Rose Perri, the Company's Chief Operating Officer. Generex Oral-lyn is the Company's flagship product, a proprietary oral insulin spray product which has been approved by the Ecuadorian Ministry of Public Health for the treatment of Type-1 and Type-2 diabetes.
The Company currently holds an aggregate of 71 patents (19 of which are United States patents) and has an aggregate 58 patent applications pending in various jurisdictions.
About Generex
Mentioned Last Change
GNBT 3.2245 (Unchanged)
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex reports positive results for oral insulin product
Print | | Disable live quotes By Val Brickates Kennedy
Last Update: 2:13 PM ET Mar 15, 2006
BOSTON (MarketWatch) -- Generex (GNBT : generex biotechnology cp del com
News , chart, profile, more
Last: 0.000.000.00%
7:28am 03/23/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GNBT0.00, 0.00, 0.0%) said Wednesday that preliminary study results show its orally-administered insulin product, Oral-lyn, was effective in controlling blood sugar levels in adolescents and young adults with type 1 diabetes. The results are from data collected during the first ten weeks of a six-month long clinical trial. As opposed to traditional insulin, which is injected, Oral-lyn is administered into the mouth via a spray. Although the product is on the market in Ecuador, Oral-lyn has not yet been given U.S. regulatory approval. Generex shares were up almost 7% at $2.26 in afternoon trade.
Generex Biotechnology Announces Additional Preliminary Results in a Trial of Generex Oral-lyn(TM) in Adolescent / Young Adult Patients With Type-1 Diabetes
E-mail or Print this story
15 March 2006, 08:30am ET
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today additional preliminary results (10 weeks) of a long-term (six month) clinical trial of Generex Oral-lyn, the Company's proprietary oral insulin spray product, in adolescent and young adult patients with Type-1 diabetes mellitus. This data, which complements the positive data announced by the Company on March 8, 2006, shows the variations of glycosylated hemoglobin (HbA1c), a very well-known marker for monitoring diabetes, during the first 10 weeks of the study.
Glycosylated hemoglobin (HbA1c) is considered by regulatory agencies and endocrinologists as the best long-term measure of metabolic control of diabetes. "HbA1c correlates with the level of risk for diabetes complications," said Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs. "The continuous and dramatic reduction seen in these preliminary results bode well for patients with diabetes, and society generally, in reducing the burdens of diabetes and its complications."
The investigators concluded that, during the first 10 weeks of this ongoing six-month trial, replacement of subcutaneous injections of regular insulin by Generex Oral-lyn at lunchtime in adolescent and young adult patients with Type-1 diabetes was associated with overall adequate glycemic control and similar glycosylated hemoglobin (HbA1c) concentrations.
About Generex
Mentioned Last Change
GNBT 3.2245 (Unchanged)
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Company Expands Drug Delivery Platform Patent Portfolio
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today that it has been granted a patent by the Mexico National Registry of Patents titled "Proteinic Drug Delivery System Using Aerosolized Membrane-Mimetic Amphiphiles." The patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals, particularly through the oral and nasal membranes.
The patent covers formulations for the delivery of peptidic drugs, vaccines, and hormones and enhances the Company's existing drug delivery platform patent portfolio.
"We are pleased to augment our Latin American patent protection as we continue with our Generex Oral-lyn(TM) commercialization efforts in the region," said Rose Perri, the Company's Chief Operating Officer. Generex Oral-lyn is the Company's flagship product, a proprietary oral insulin spray product which has been approved by the Ecuadorian Ministry of Public Health for the treatment of Type-1 and Type-2 diabetes.
The Company currently holds an aggregate of 71 patents (19 of which are United States patents) and has an aggregate 58 patent applications pending in various jurisdictions.
About Generex
Mentioned Last Change
GNBT 3.2245 (Unchanged)
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex reports positive results for oral insulin product
Print | | Disable live quotes By Val Brickates Kennedy
Last Update: 2:13 PM ET Mar 15, 2006
BOSTON (MarketWatch) -- Generex (GNBT : generex biotechnology cp del com
News , chart, profile, more
Last: 0.000.000.00%
7:28am 03/23/2006
Add to portfolio
Analyst
Create alertInsider
Discuss
Financials
Sponsored by:
GNBT0.00, 0.00, 0.0%) said Wednesday that preliminary study results show its orally-administered insulin product, Oral-lyn, was effective in controlling blood sugar levels in adolescents and young adults with type 1 diabetes. The results are from data collected during the first ten weeks of a six-month long clinical trial. As opposed to traditional insulin, which is injected, Oral-lyn is administered into the mouth via a spray. Although the product is on the market in Ecuador, Oral-lyn has not yet been given U.S. regulatory approval. Generex shares were up almost 7% at $2.26 in afternoon trade.
Generex Biotechnology Announces Additional Preliminary Results in a Trial of Generex Oral-lyn(TM) in Adolescent / Young Adult Patients With Type-1 Diabetes
E-mail or Print this story
15 March 2006, 08:30am ET
Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, announced today additional preliminary results (10 weeks) of a long-term (six month) clinical trial of Generex Oral-lyn, the Company's proprietary oral insulin spray product, in adolescent and young adult patients with Type-1 diabetes mellitus. This data, which complements the positive data announced by the Company on March 8, 2006, shows the variations of glycosylated hemoglobin (HbA1c), a very well-known marker for monitoring diabetes, during the first 10 weeks of the study.
Glycosylated hemoglobin (HbA1c) is considered by regulatory agencies and endocrinologists as the best long-term measure of metabolic control of diabetes. "HbA1c correlates with the level of risk for diabetes complications," said Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs. "The continuous and dramatic reduction seen in these preliminary results bode well for patients with diabetes, and society generally, in reducing the burdens of diabetes and its complications."
The investigators concluded that, during the first 10 weeks of this ongoing six-month trial, replacement of subcutaneous injections of regular insulin by Generex Oral-lyn at lunchtime in adolescent and young adult patients with Type-1 diabetes was associated with overall adequate glycemic control and similar glycosylated hemoglobin (HbA1c) concentrations.
About Generex
Mentioned Last Change
GNBT 3.2245 (Unchanged)
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex Web site at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Hatte die seit 1,5x
bin gestern auf TH raus im BS
real bei 3
etwas spät dein Thread
bin gestern auf TH raus im BS
real bei 3etwas spät dein Thread
nichts desto trotz,
kurs aktuell +10% vorbörslich 3,55 USD
kurs aktuell +10% vorbörslich 3,55 USD
hab die aktie schon bei 0,96€ empfohlen. da bin ich nämlich das erste mal eingestiegen
Trading Spotlight
hier jetzt noch rein...hm.
also meiner Meinung nach ist das Chance/Risiko/Verhältnis bei Biota besser.Erst heute gab es eine weiter Order von der US Regierung,siehe:
http://www.finanznachrichten.de/nachrichten-2006-03/artikel-…
bzw.http://www.theage.com.au/news/Business/US-govt-orders-Biotas…
also meiner Meinung nach ist das Chance/Risiko/Verhältnis bei Biota besser.Erst heute gab es eine weiter Order von der US Regierung,siehe:
http://www.finanznachrichten.de/nachrichten-2006-03/artikel-…
bzw.http://www.theage.com.au/news/Business/US-govt-orders-Biotas…
Mit Viren tut sich die Medizinierung recht schwer.
AIDS, Herpes, Chlamydien -Viren etc. sind unbesiegr.
Der Vogelgrippevirus ist noch resistenter,
da er die hohe Eigentemperatur bei Zugvoegel spielend ueberlebt.
Jede Spekulation auf neue Heilmittel scheinen daher einer serioesen Kapitalanlage nicht zu dienen.
AIDS, Herpes, Chlamydien -Viren etc. sind unbesiegr.
Der Vogelgrippevirus ist noch resistenter,
da er die hohe Eigentemperatur bei Zugvoegel spielend ueberlebt.
Jede Spekulation auf neue Heilmittel scheinen daher einer serioesen Kapitalanlage nicht zu dienen.
kyron
selbst wenn dem so wäre,können und werden Unternehmen trotzdem daran verdienen.oder willst Du bestreiten,dass mit Tamiflu und Relenza kein Geld gemacht wird
.
siehe:http://www.spiegel.de/wissenschaft/mensch/0,1518,403039,00.h…
selbst wenn dem so wäre,können und werden Unternehmen trotzdem daran verdienen.oder willst Du bestreiten,dass mit Tamiflu und Relenza kein Geld gemacht wird
.siehe:http://www.spiegel.de/wissenschaft/mensch/0,1518,403039,00.h…
Ja Buddah,
es wird sogar ueber Volkszwangsimpfungen nachgdacht, mit dem giftigen und schwach radioaktivem Tamiflu.
Rumsfeld wird es begruessen oder gar bewerkstelligen,
er verdient Millionen damit.
es wird sogar ueber Volkszwangsimpfungen nachgdacht, mit dem giftigen und schwach radioaktivem Tamiflu.
Rumsfeld wird es begruessen oder gar bewerkstelligen,
er verdient Millionen damit.
kyron
lasse mich selbst auch nicht Impfen und glaube irgendwie auch nicht an die Virentheorie
Gruss B.
lasse mich selbst auch nicht Impfen und glaube irgendwie auch nicht an die Virentheorie
Gruss B.
Antwort auf Beitrag Nr.: 20.924.229 von Buddah am 23.03.06 17:18:31
...hallo ! Lese heute,dass das Vogelgrippevirus sehr schwer von Mensch zu Mensch übertragbar ist.Es besteht keine Ansteckungsgefahr über "Tröpfcheninfektion,da sich das Teil ganz unten in den Lungenzellen einnistet und nicht,wie das normale Grippevirus im Rachenraum und in den Bronchien.GRUSS VIERLANT.
...hallo ! Lese heute,dass das Vogelgrippevirus sehr schwer von Mensch zu Mensch übertragbar ist.Es besteht keine Ansteckungsgefahr über "Tröpfcheninfektion,da sich das Teil ganz unten in den Lungenzellen einnistet und nicht,wie das normale Grippevirus im Rachenraum und in den Bronchien.GRUSS VIERLANT.
Antwort auf Beitrag Nr.: 20.935.142 von VIERLANT am 24.03.06 11:30:41...ach so,wichtig ist noch,dass es ,bevor es zur Pandemiegefahr werden würde,noch einige Male mutieren müsste ! Das kann natürlich einteten.Aber die globalen Vorsichtsmaßnahmen und die allgemeine Aufmerksamkeit auf den Ausbruch dieser Gefahr ,wiegt mich doch in ziemlicher Sicherheit.
Antwort auf Beitrag Nr.: 20.935.236 von VIERLANT am 24.03.06 11:37:01Sicherheit vor Ansteckung kann es nicht geben.
Es kommt doch sehr auf den Zustand des Immunsystems an.
Das Immunsystem ist eigentlich perfekt, damit haben wir seit
Millionen von Jahren ueberlebt.
Allerdings bauen wir das Immunsystem durch industrielle Nahrumgsmittel ab.
Durch die Wachstumshemmer und Herbizide wurde z.B. der Weizen
ungeniessbar und der Genuss von Weizen fuehrt zur Allergie.
Wer von einem Virus in einem Allergiezustand erwischt wird,
ist in Schwierigkeiten.
Daneben sind auch Milchprodukte, Erdnuesse, Geschmacksverstaerker,
Farbstoffe, uva. auch als Allergieerzeuger bekannt.
Es kommt doch sehr auf den Zustand des Immunsystems an.
Das Immunsystem ist eigentlich perfekt, damit haben wir seit
Millionen von Jahren ueberlebt.
Allerdings bauen wir das Immunsystem durch industrielle Nahrumgsmittel ab.
Durch die Wachstumshemmer und Herbizide wurde z.B. der Weizen
ungeniessbar und der Genuss von Weizen fuehrt zur Allergie.
Wer von einem Virus in einem Allergiezustand erwischt wird,
ist in Schwierigkeiten.
Daneben sind auch Milchprodukte, Erdnuesse, Geschmacksverstaerker,
Farbstoffe, uva. auch als Allergieerzeuger bekannt.
völlig richtig kyron.
wie unfähig unsere von allen verehrte Schulmedizin ist verdeutlicht dieser Artikel:
Gesundheit
Das Mysterium Schnupfen
Die Menschheit mag die Pest besiegt haben und die Pocken. Von der banalen Erkältung aber lässt sie sich immer noch quälen. Und das Einzige, was offenbar hilft, sind alte Hausmittel.
Von Christina Berndt
http://www.sueddeutsche.de/wissen/artikel/936/47889/
wie unfähig unsere von allen verehrte Schulmedizin ist verdeutlicht dieser Artikel:
Gesundheit
Das Mysterium Schnupfen
Die Menschheit mag die Pest besiegt haben und die Pocken. Von der banalen Erkältung aber lässt sie sich immer noch quälen. Und das Einzige, was offenbar hilft, sind alte Hausmittel.
Von Christina Berndt
http://www.sueddeutsche.de/wissen/artikel/936/47889/
Antwort auf Beitrag Nr.: 20.939.080 von Buddah am 24.03.06 15:46:49...kein Dissenz,kyron.
Grüsse euch,VIERLANT.
Grüsse euch,VIERLANT.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 294 | ||
| 109 | ||
| 107 | ||
| 77 | ||
| 70 | ||
| 60 | ||
| 57 | ||
| 48 | ||
| 45 | ||
| 44 |
| Wertpapier | Beiträge | |
|---|---|---|
| 33 | ||
| 28 | ||
| 27 | ||
| 27 | ||
| 25 | ||
| 22 | ||
| 21 | ||
| 20 | ||
| 18 | ||
| 18 |
